Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia

被引：30

作者：

Ayala, Rosa M. ^{[1
]}

Martinez-Lopez, Joaquin ^{[1
]}

Albizua, Enriqueta ^{[1
]}

Diez, Amalia ^{[2
]}

Gilsanz, Florinda ^{[1
]}

机构：

[1] Hosp Univ 12 Octubre, Serv Hematol, Madrid 28041, Spain

[2] Univ Complutense Madrid, Dept Bioquim & Biol Mol 4, E-28040 Madrid, Spain

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2009年 / 84卷 / 02期

关键词：

TRANSCRIPTION FACTOR GATA-1; GENE-EXPRESSION; MEGAKARYOBLASTIC LEUKEMIA; MYELODYSPLASTIC SYNDROME; PROGNOSTIC-SIGNIFICANCE; NORMAL CYTOGENETICS; NORMAL KARYOTYPE; CEBPA MUTATIONS; MESSENGER-RNA; AML1; GENE;

D O I：

10.1002/ajh.21332

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The aim of this study was to evaluate the biological correlation and prognostic impact of Gata-1, Gata-2, EKLF, and c-MPL transcript level in a group of 41 acute mieloid leukemia (AML) patients. Gata-1 overexpression was related to advanced age and a low percentage of bone marrow blasts and was associated with the expression of CD34 antigen and lymphoid T markers. The negative impact of Gata-1 expression on the probability of achieving complete remission has been confirmed. Gata-2 overexpression was associated with a low percentage of blasts in BM and males. Expression of c-MPL was associated with CD34+ AML and M2 FAB AML subtype. A higher expression of EKLF was found in secondary AML versus primary AML. Nevertheless, patients expressing EKLF had a longer overall survival and event free survival than those patients that did not express EKLF. Our study has identified expression of EKLF as a factor with a favorable Impact on prognosis in AML. Am. J. Hematol. 84:79-86, 2009. (C) 2008 Wiley-Liss, Inc.

引用

页码：79 / 86

页数：8

共 66 条

[1] Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia [J].

Aguayo, A ;

Estey, E ;

Kantarjian, H ;

Mansouri, T ;

Gidel, C ;

Keating, M ;

Giles, F ;

Estrov, Z ;

Barlogie, B ;

Albitar, M .

BLOOD, 1999, 94 (11) :3717-3721

[2] Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia [J].

Albitar, M ;

Manshouri, T ;

Kantarjian, H ;

Keating, M ;

Estrov, Z ;

Faber, J ;

Freireich, EJ ;

Pierce, S ;

Estey, E .

LEUKEMIA RESEARCH, 1999, 23 (01) :63-69

[3] Transcription of chromatin: these are complex times [J].

Armstrong, JA ;

Emerson, BM .

CURRENT OPINION IN GENETICS & DEVELOPMENT, 1998, 8 (02) :165-172

[4] BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics:: Prognostic implications [J].

Baldus, CD ;

Thiede, C ;

Soucek, S ;

Bloomfield, CD ;

Thiel, E ;

Ehninger, G .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (05) :790-797

[5] Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21:: Amplification discloses overexpression of APP, ETS2, and ERG genes [J].

Baldus, CD ;

Liyanarachchi, S ;

Mrózek, K ;

Auer, H ;

Tanner, SM ;

Guimond, M ;

Ruppert, AS ;

Mohamed, N ;

Davuluri, RV ;

Caligiuri, MA ;

Bloomfield, CD ;

de la Chapelle, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (11) :3915-3920

[6] PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS [J].

BENNETT, JM ;

CATOVSKY, D ;

DANIEL, MT ;

FLANDRIN, G ;

GALTON, DAG ;

GRALNICK, HR ;

SULTAN, C .

BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) :451-&

[7]

BERMAN E, 1991, BLOOD, V77, P1666

[8] Risk assessment in patients with acute myeloid leukemia and a normal karyotype [J].

Bienz, M ;

Ludwig, M ;

Mueller, BU ;

Leibundgut, EO ;

Ratschiller, D ;

Solenthaler, M ;

Fey, MF ;

Pabst, T .

CLINICAL CANCER RESEARCH, 2005, 11 (04) :1416-1424

[9]

Bolufer P, 2002, HAEMATOLOGICA, V87, P23

[10] EKLF restricts megakaryocytic differentiation at the benefit of erythrocytic differentiation [J].

Bouilloux, Fabrice ;

Juban, Gaetan ;

Cohet, Nathalie ;

Buet, Dorothee ;

Guyot, Boris ;

Vainchenker, William ;

Louache, Fawzia ;

Morle, Francois .

BLOOD, 2008, 112 (03) :576-584

← 1 2 3 4 5 6 7 →